Mankind Pharma Q2 FY27 Profit Jumps 38% to ₹716 Crore as Chronic Therapies Drive Domestic Growth
Mankind Pharma’s Q2 FY27 net profit rose 37.7% to ₹716 crore on 17.3% revenue growth to ₹4,338 crore, led by cardiac and anti-diabetes demand in India, 33% export growth and a 210 bps EBITDA margin expansion to 27.1%.
